Merriman Curhan Ford reiterated their Buy rating and $10-$13 price target range on Halozyme Therapeutics (Nasdaq: HALO) after Phase II ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE